Sara N. Hanson

发表

Postacute Sequelae of SARS-CoV-2 Infection—Lessons Learned From a Coordinated Health System Response

I. Croghan, A. A. Abu Dabrh, R. Hurt, 2022, Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019

Ryan J. Anderson, S. Tulledge-Scheitel, L. Philpot, 2021, The Journal of infectious diseases.

Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities

S. Tulledge-Scheitel, R. Razonable, Ravindra Ganesh, 2021, medRxiv.

Curbing the Delta Surge

S. Tulledge-Scheitel, R. Razonable, Ravindra Ganesh, 2022, Mayo Clinic Proceedings.

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

S. Tulledge-Scheitel, R. Razonable, Ravindra Ganesh, 2022, The Journal of infectious diseases.

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.

A. Venkatakrishnan, C. Pawlowski, S. Tulledge-Scheitel, 2021, The Journal of clinical investigation.

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch

S. Tulledge-Scheitel, R. Razonable, Ravindra Ganesh, 2022, Open forum infectious diseases.

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant

S. Tulledge-Scheitel, R. Razonable, Ravindra Ganesh, 2021, Mayo Clinic Proceedings.

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19

Karen J. Reinschmidt, S. Tulledge-Scheitel, L. Lutwick, 2021, Mayo Clinic Proceedings.

Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19

L. Philpot, R. Razonable, Ravindra Ganesh, 2021, Journal of primary care & community health.

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score

R. Carter, C. Libertin, R. Razonable, 2023, Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

A. Venkatakrishnan, C. Pawlowski, S. Tulledge-Scheitel, 2021, EClinicalMedicine.

Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19

A. Venkatakrishnan, C. Pawlowski, S. Tulledge-Scheitel, 2021, medRxiv.

A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities

Karen J. Reinschmidt, S. Tulledge-Scheitel, P. Takahashi, 2021, Journal of the American Geriatrics Society.